Literature DB >> 35648024

Comment on: Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield) - A case report and review of literature.

Bharat Gurnani1, Kirandeep Kaur1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35648024      PMCID: PMC9359288          DOI: 10.4103/ijo.IJO_264_22

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   2.969


× No keyword cloud information.
Dear Editor, The COVID-19 pandemic resulted in high mortality during the second wave, and the vaccine came as a savior. The vaccine has been reported to trigger a robust immune response, and whether or not the vaccine invites graft rejection remains a theoretical concern.[1] We read the important case report by Rajagopal et al.[2] on stromal rejection in penetrating keratoplasty following the COVID-19 vaccine, and we must congratulate the authors for reporting this case. However, we have a few critical observations and suggestions to make. Firstly, the authors have reported graft rejection episodes after 6 weeks of the second dose of Covishield. There is a long duration between the second dose and clinical symptoms, which is the longest as per the literature reviews. This can probably be a systemic immune rejection. How did the authors rule that out? Secondly, the first COVID vaccination history is also significant in this case. Did the patient have any ocular symptoms post first dose vaccination? Most patients had systemic symptoms such as fever, myalgia, and cough after the first vaccine due to robust immune response post COVID antigen administration. These symptoms could also potentially trigger a graft rejection episode.[3] Thirdly, was the patient on a maintenance dose of steroids to prevent graft rejection?[4] Did the patient have a drug holiday that could have triggered the inflammatory cascade and stromal rejection episode? The treatment history of pre- and post-stromal rejection episodes is missing. Can the authors throw some light on this? Lastly, the patient is a known case of Hodgkin’s lymphoma. Was it ocular or systemic? Was the patient on any immunosuppressants currently? This can be another trigger for immunosuppression and graft rejection episodes. The authors have reported an interesting case; however, because the duration is long and the patient did not report any systemic symptoms, it can be merely a chance association. Once again, we congratulate the authors for bringing out this important case.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

Review 1.  Literature review and suggested protocol for prevention and treatment of corneal graft rejection.

Authors:  Otavio Azevedo Magalhaes; Ahmed Shalaby Bardan; Mehran Zarei-Ghanavati; Christopher Liu
Journal:  Eye (Lond)       Date:  2019-07-22       Impact factor: 3.775

2.  Corneal graft rejection following COVID-19 vaccine.

Authors:  Konstantinos I Rallis; Darren S J Ting; Dalia G Said; Harminder S Dua
Journal:  Eye (Lond)       Date:  2021-08-23       Impact factor: 3.775

Review 3.  Ocular Adverse Events After COVID-19 Vaccination.

Authors:  Xin Le Ng; Bjorn Kaijun Betzler; Ilaria Testi; Su Ling Ho; Melissa Tien; Wei Kiong Ngo; Manfred Zierhut; Soon Phaik Chee; Vishali Gupta; Carlos E Pavesio; Marc D de Smet; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2021-09-24       Impact factor: 3.070

Review 4.  Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield) - A case report and review of literature.

Authors:  Rama Rajagopal; T Maria Priyanka
Journal:  Indian J Ophthalmol       Date:  2022-01       Impact factor: 2.969

  4 in total
  1 in total

Review 1.  Response to comment on: Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covishield): A case report and review of literature.

Authors:  Rama Rajagopal; T Maria Priyanka
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.